KalVista Pharmaceuticals Inc · Q1 2022 earnings

Briefing

KalVista reported financial results for the first fiscal quarter ended July 31, 2021.

KalVista Pharmaceuticals reported no revenue for the three months ended July 31, 2021. Research and development expenses were $13.7 million, and general and administrative expenses were $5.9 million. The net loss was $16.1 million, or $(0.66) per share. Cash, cash equivalents, and marketable securities totaled $230.6 million as of July 31, 2021.

• Presented Phase 2 data for KVD900 at EAACI Congress, showing it significantly slows progression and accelerates resolution of HAE attacks.
• Scheduled an end-of-Phase 2 meeting with the FDA to review development plans for KVD900, expected in September 2021.
• Provided a progress update on the KVD824 Phase 2 KOMPLETE Clinical Trial, with patient enrollment underway in Canada, Australia, and the UK.
• Net loss was $16.1 million, or $(0.66) per share, for the quarter ended July 31, 2021, compared to a net loss of $10.8 million, or $(0.61) per share, for the same period in the prior fiscal year.

Headline financials

Revenue & EPS history

This press release contains forward-looking statements regarding the safety and efficacy of product candidates, timing of clinical trials and results, ability to commence or complete clinical studies, ability to obtain regulatory approvals, the ability of product candidates to treat HAE or DME, the future progress and potential success of programs, and the sufficiency of cash to fund operations.